1
Home
Companies

Achilles Therapeutics

Achilles Therapeutics
Leadership team

Dr. Iraj Ali (CEO & Director)

Dr. Karl Peggs M.D. (Founder & Chief Medical Officer)

Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. (Founder)

Products/ Services
Biotechnology, Health Care, Therapeutics, Wellness
Number of Employees
100 - 500
Headquarters
London, England, United Kingdom
Established
2016
Company Registration
SEC CIK number: 0001830749
Traded as
NASDAQ:ACHL
Social Media
URL
https://www.achillestx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
History

Achilles Therapeutics was founded in 2018 by a group of successful entrepreneurs. The founders were interested in leveraging the power of T-cell therapies to treat cancer and dedicated their resources to create the company.

Mission
Achilles Therapeutics is dedicated to the research, development, and commercialization of personalized T-cell therapies to cure and treat cancer.
Vision
Achilles Therapeutics seeks to bring the power of personalized T-cell therapy to all cancer patients in an accessible and safe manner.
Key Team

Dr. Charles Swanton FMEDSCI, M.D., Ph.D. (Founder)

Mr. Lee M. Stern (VP of Investor Relations & External Communications)

Dr. Sergio A. Quezada Ph.D. (Founder & Chief Scientific Officer)

Mr. Daniel Hood (Gen. Counsel & Company Sec.)

Mr. Robert Coutts (Chief Financial Officer)

Julia Wilson (Head of Communications)

Mr. Tariq Ahmed (VP of People)

Recognition and Awards
Achilles Therapeutics is the winner of the 2019 ELR Excellence in Translational Research Award and the 2020 Scrip Award for Regulatory Achievement.
References

https://in.investing.com/equities/achilles-therapeutics-adr

https://finance.yahoo.com/quote/ACHL/profile?p=ACHL

https://www.crunchbase.com/organization/achilles-therapeutics

https://www.achillestx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Achilles Therapeutics
Leadership team

Dr. Iraj Ali (CEO & Director)

Dr. Karl Peggs M.D. (Founder & Chief Medical Officer)

Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. (Founder)

Products/ Services
Biotechnology, Health Care, Therapeutics, Wellness
Number of Employees
100 - 500
Headquarters
London, England, United Kingdom
Established
2016
Company Registration
SEC CIK number: 0001830749
Traded as
NASDAQ:ACHL
Social Media
URL
https://www.achillestx.com